In women, circulating GDF-15 concentrations are increased with type 2 diabetes and correlate with body mass index (BMI), body fat, glucose, and C-reactive protein (CRP) (13 ) .
The relation of GDF-15 to BMI, and to obesity comorbidities such as diabetes, inflammation, endothelial dysfunction, and cardiovascular disease, highlight the importance of characterizing GDF-15 in obese patients. Here we studied the relationship of GDF-15 with anthropometrical measurements of obesity, blood pressure, parameters of glucose and lipid metabolism, inflammation, and renal function in a cohort of 118 morbidly obese patients vs 30 age-and sexmatched healthy individuals, and in 28 patients who underwent laparoscopic Roux-en-Y gastric bypass surgery (RYGB).
Study Participants and Methods

STUDY PARTICIPANTS AND DESIGN
The study protocol was approved by the institutional review board of the Medical University of Vienna. Thirty healthy individuals and 118 obese individuals were evaluated in a cross-sectional study. Inclusion criteria for the healthy individuals were BMI Ͻ25 kg/m 2 and no previous medical history. The obese patients were recruited from the obesity outpatient clinic of the Division of Endocrinology and Metabolism, and inclusion criteria were BMI Ͼ35 kg/m 2 and no previously diagnosed diabetes mellitus. Exclusion criteria were positive medical history for coronary heart disease, heart failure, peripheral artery disease, stroke, malignancy, and chronic liver, renal, or endocrine disease. During the study day, participants underwent a thorough medical examination. Weight was measured to the nearest 100 g. Height, waist, and hip circumference were measured to the nearest centimeter. BMI was calculated as weight in kilograms divided by the square of height in meters. Blood pressure was measured on the left arm by use of a sphygmomanometer and a cuff appropriate for the arm circumference, after the study participant had been sitting for 10 min. Mean arterial pressure (MAP) was calculated as (2 ϫ diastolic blood pressure ϩ systolic blood pressure)/3. Blood samples were withdrawn for the measurement of triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, CRP, creatinine, albumin, and hemoglobin A 1c (Hb A 1c ) at baseline. Blood samples for the measurement of GDF-15 were collected in tubes containing EDTA, centrifuged at 1500g for 10 min, and immediately frozen at Ϫ20°C. Then, an oral glucose tolerance test (OGTT) was performed using 75 g glucose. The homeostasis model assessment (HOMA) insulin resistance index was calculated as the product of fasting glucose (in mg/ dL) and insulin (in mU/L) divided by the constant 405. The oral glucose insulin sensitivity (OGIS) was calculated as explained in http://webmet.pd.cnr.it/ogis (14 ) . The clamp-like insulin resistance index (CLIX) was calculated as previously reported (15 ) . We calculated the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease formula (16 ) .
In an interventional study, 28 obese patients scheduled to undergo RYGB surgery were studied at 2 time points: before and 1 year after the intervention. At both study days, a clinical examination was performed; weight, height, and waist circumference were measured; and blood samples were withdrawn according to the same protocol used in the cross-sectional study and explained above.
ASSAYS
We measured human GDF-15 using a quantitative sandwich ELISA kit (# DGD150, R&D Systems) with intraand interassay CVs of Ͻ2.8% and Ͻ6%, respectively. Insulin and C peptide were determined by using commercially available RIAs (LINCO Research). Leptin was measured by using the Human Fluorokine MAP Base Kit (Obesity Panel) and the Leptin Fluorokine MAP (R&D Systems). Fasting glucose, triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, albumin, CRP, creatinine, and Hb A 1c were quantified by using routine tests in a certified clinical laboratory.
STATISTICAL ANALYSIS
Data distributions were tested for normality by using histograms. Normally distributed data are expressed as mean (SE), nonnormally distributed data are presented as median and interquartile range (IQR). Differences between the groups were tested by using the Bonferroni-Holm-corrected 2-sided independentsamples t-test for parametric data and the MannWhitney U-test for nonnormally distributed data (such as GDF-15). Spearman rank correlations were computed to assess the relationship between variables. Multiple regression analyses were performed for identifying independent relationships and adjusting the effects of covariates. Nonnormally distributed parameters (GDF-15, creatinine, insulin, C-peptide, HOMA insulin resistance index, and triglycerides) were logarithmically transformed before regression analyses. Differences in GDF-15 between the 4 subgroups [healthy, obese with normal glucose tolerance (NGT), obese with impaired glucose tolerance (IGT), and obese with type 2 diabetes mellitus (DM)] were tested by use of one-way ANOVA followed by post hoc t-tests with Bonferroni correction for multiple testing. In the interventional study, differences between baseline and post-RYGB values were tested using a Bonferroni-Holm-corrected paired Student t-test. The statistical software package SPSS release 15.0.1 (SPSS) was used. P values Ͻ 0.05 were considered statistically significant.
Results
Clinical, biochemical, and metabolic characteristics of participants of the cross-sectional study are given in Table 1 . Median (IQR) plasma GDF-15 concentrations were 309 (275-411) ng/L in healthy individuals and 427 (344 -626) ng/L in obese patients (P Ͻ 0.001) (Fig. 1) .
In the obese cohort, GDF-15 concentrations were significantly correlated with age, waist circumference (and waist-to-height ratio), MAP, fasting glucose, fasting insulin, fasting C-peptide, Hb A 1c , HOMA insulin resistance index, and fasting triglycerides and creatinine and negatively correlated with OGIS ( Table 2 , Fig.  2 A-B). GDF-15 was not associated with renal function (GFR) or CRP ( Table 2) . Multiple regression analysis revealed that age, HOMA insulin resistance index, OGIS, and creatinine were independent predictors of circulating GDF-15 concentrations (Table 3 ). The correlations between GDF-15 and MAP and fasting triglycerides and fasting glucose disappeared when GDF-15 was adjusted for age. The correlations between GDF-15 and waist circumference and fasting insulin and fasting C-peptide remained significant after we adjusted GDF-15 for age and creatinine, but disappeared after an additional adjustment for HOMA insulin resistance index and OGIS. Arterial hypertension was present in 49 patients (41%). There were no significant differences in plasma GDF-15 between patients with and without hypertension.
When data from all participants (healthy and obese individuals) were taken together, all the above relationships between GDF-15 and anthropometric or metabolic parameters remained significant. In addition, GDF-15 was weakly but significantly related to BMI, CRP, and CLIX (Table 2 ), but not to GFR.
Obese patients were subdivided according to OGTT results: 69 patients with NGT, 35 patients with IGT, and 14 patients with newly diagnosed DM (Fig.  2C) . GDF-15 was significantly increased in all of these subgroups compared to the healthy control group (P ϭ 0.001 for comparison between healthy and NGT; P Ͻ 0.001 for comparison between healthy and IGT; P Ͻ 0.001 for comparison between healthy and DM; Fig. 2D ). There were no significant differences in age between healthy study participants and those in the NGT, IGT, and DM groups. Within the obese cohort, patients with DM had significantly higher GDF-15 concentrations (P ϭ 0.016) and were significantly older (P ϭ 0.028) compared to patients with NGT (Fig. 2D) . Differences in age and GDF-15 between other obese subgroups were not found to be significant. In the interventional study, we measured GDF-15 concentrations in 28 individuals undergoing laparoscopic RYGB surgery, at baseline and 1 year after the intervention. RYGB-induced changes in clinical, biochemical, and metabolic parameters are presented in Table 4 . GDF-15 significantly increased from 474 (31) to 637 (52) ng/L after bariatric surgery, P ϭ 0.001 both before and after exclusion of the outlier value (173% increase in GDF-15 after bariatric surgery) (Fig. 2E) . One year after RYGB, the correlation between GDF-15 and age remained significant (R ϭ 0.495, P ϭ 0.009), whereas all other associations did not. The RYGB-induced increase in GDF-15 was positively associated with the decreases in BMI (R ϭ 0.541, P ϭ 0.004) and in the HOMA insulin resistance index (R ϭ 0.622, P ϭ 0.003) (Fig. 2F) .
Discussion
GDF-15 is known as a stress-induced cytokine that increases in response to cardiovascular dysfunction and carries prognostic information on cardiovascular mortality in healthy people and in patients with known cardiovascular disease (3, 11 ) . The main finding of this study was that GDF-15 is related to all parameters characterizing glucose metabolism and is positively correlated to glucose, insulin, C-peptide, Hb A 1c , and HOMA insulin resistance index, and negatively correlated to the oral glucose insulin sensitivity (measured as OGIS). HOMA insulin resistance index and OGIS were both independent predictors of GDF-15 in obese patients. We included both HOMA and OGIS in the multiple regression analysis because they are used to estimate different processes. The HOMA insulin resistance index is a parameter that is calculated by using fasting glucose and insulin concentrations and reflects mainly hepatic, but not peripheral, insulin resistance (17 ) . OGIS is an indicator of insulin sensitivity in response to OGTT and therefore reflects mainly glucose clearance and muscle sensitivity to insulin (14 ) .
GDF-15 concentrations were not related to renal function (measured as GFR), but were predicted by creatinine, a parameter known to reflect muscle mass in individuals with normal renal function (18 ) . GDF-15 was higher in obese patients with newly diagnosed DM compared to obese patients with NGT. Nev- ertheless, obese patients with diabetes were a small and older subgroup of our cohort. Whether GDF-15 concentrations are increased in patients with DM compared to age-and sex-matched healthy individuals remains to be evaluated in further studies. The strongest predictor of GDF-15 in obese individuals was age, a parameter that outranks all modifiable cardiovascular risk factors in the cardiovascular risk stratification (19 ) . In addition, GDF-15 was strongly associated with the waist-to-height ratio, but not to BMI in obese individuals (despite the wide BMI range: 37-62 kg/m 2 ). Recently, the measurements of abdominal obesity, and especially the waist-to-height ratio, have been identified to have a better cardiovascular predictive value compared to BMI (20 ) . In summary, the strong relationships between GDF-15 and age, insulin resistance, creatinine, and waist-to-height ratio taken together might contribute to the increased prognostic information of GDF-15 compared with other clinical and biochemical markers of cardiovascular risk (3 ) . In addition to cardiovascular disease, GDF-15 has been linked to inflammation and cancer (21 ) . Macrophages, endothelial cells, and cardiomyocytes comprise the main sources of GDF-15 (5, 6, 7 ) . In vitro studies have found increased GDF-15 release after tissue injury, anoxia, and stimulation with proinflammatory cytokines such as tumor necrosis factor-␣, but not with lipopolysaccharide (5 ) . Inflammation has been implicated in the pathophysiology of atherosclerotic plaques and therefore in cardiovascular events (22 ) . Obesity is associated with a mild systemic inflammation and, as expected, we found a mild but significant relationship between GDF-15 and CRP in the whole cohort comprising healthy and obese individuals. Nevertheless, this relationship disappeared within the obese cohort, revealing the independence of GDF-15 concentrations from the degree of systemic inflammation in obesity. Given the fact that GDF-15 is secreted by adipocytes and therefore considered to be an adipokine, we assumed that GDF-15 concentrations are altered in obese individuals (12 ) . Nevertheless, results of a recent study demonstrated increased circulating GDF-15 concentrations in obese individuals, but no differences at the level of gene expression within the adipose tissue (13 ) . The pathophysiological mechanism underlying increased GDF-15 concentrations in obesity remains unknown and may not be linked only to adipose tissue. Endothelial dysfunction, cardiac stress, ␤-cell function, and insulin resistance may all contribute to the changes in GDF-15. In the light of the strong association between GDF-15 and parameters of glucose metabolism, it is important to identify the influence of GDF-15 on ␤-cell function and glucose uptake and vice versa, an eventual effect of glucose and insulin on GDF-15 release.
Bariatric surgery is to date the only efficient therapeutic means for achieving weight loss in individuals with severe obesity. Our observation that RYGB surgery significantly decreased body weight, leptin, CRP, insulin, and HOMA insulin resistance index confirmed the results of previous studies (23, 24 ) . Nevertheless, GDF-15 concentrations increased further. The RYGBinduced increase in GDF-15 was significantly correlated with age. The strong association with insulin resistance was noticeable even during the changes following bariatric surgery, because obese patients with larger reductions in weight and insulin resistance had smaller increases in GDF-15 (Fig. 2F) . Nevertheless, these results suggest an indirect association between GDF-15 and insulin resistance, and the pathophysiological mechanisms that control postoperative GDF-15 concentrations remain unknown. It is interesting to note that GDF-15 concentrations also increase after diet-induced weight loss and in patients with anorexia nervosa (13, 25 ) . To date, it is not known whether circulating GDF-15 concentrations depend on albumin or any carrier proteins. It is important to emphasize that the increase in GDF-15 is not in line with the significant improvement in cardiovascular function that occurs following bariatric surgery (26 ) . Therefore, GDF-15 is highly likely to be an unreliable cardiovascular biomarker in patients who have undergone gastric bypass surgery.
In summary, age, insulin resistance, and creatinine were independent predictors of GDF-15 in obese patients, and these associations might contribute to the recently found increased cardiovascular prediction value of GDF-15 compared with classical predictors. Nevertheless, the increase in GDF-15 concentrations following weight loss is not in line with a direct relationship between GDF-15 and insulin resistance and/or clinical measurements of obesity. The utility of GDF-15 as a biomarker might be limited until the pathways that directly control GDF-15 concentrations in humans are better understood.
